| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 103.140 | 109.156 | 88.476 | 68.770 | 62.381 | 50.688 | 42.126 | 32.154 | 34.214 | 51.127 |
| Total Income - EUR | 103.209 | 110.591 | 88.650 | 69.434 | 63.897 | 50.688 | 42.252 | 32.154 | 34.325 | 51.127 |
| Total Expenses - EUR | 69.694 | 64.965 | 86.499 | 66.331 | 56.808 | 42.581 | 41.721 | 36.841 | 36.375 | 33.530 |
| Gross Profit/Loss - EUR | 33.515 | 45.626 | 2.152 | 3.104 | 7.088 | 8.106 | 532 | -4.687 | -2.050 | 17.597 |
| Net Profit/Loss - EUR | 28.690 | 44.521 | 440 | 2.474 | 6.449 | 7.636 | 272 | -5.002 | -2.394 | 17.086 |
| Employees | 3 | 3 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 1 |
Check the financial reports for the company - Apotest Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 21.292 | 33.526 | 25.999 | 21.099 | 24.660 | 15.505 | 8.330 | 4.185 | 3.383 | 3.389 |
| Current Assets | 108.007 | 52.097 | 47.657 | 45.924 | 62.336 | 72.973 | 70.686 | 76.728 | 65.078 | 86.067 |
| Inventories | 0 | 0 | 0 | -796 | -781 | 0 | 0 | 0 | -749 | 0 |
| Receivables | 103.885 | 50.553 | 46.708 | 46.066 | 61.777 | 72.592 | 70.287 | 71.948 | 64.627 | 74.976 |
| Cash | 4.123 | 1.544 | 949 | 654 | 1.341 | 381 | 399 | 4.779 | 1.200 | 11.091 |
| Shareholders Funds | 102.351 | 59.112 | 58.553 | 59.952 | 65.240 | 71.639 | 70.323 | 65.538 | 62.946 | 79.680 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 26.948 | 26.510 | 15.103 | 7.071 | 22.528 | 16.839 | 8.693 | 15.374 | 5.515 | 9.777 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7120 - 7120" | |||||||||
| CAEN Financial Year |
7120
|
|||||||||
Comments - Apotest Srl